Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcoma ABOSTO:ARCOMA -4.10%74 3-Year EBITDA Growth Rate is 9.60% as of Jun. 2026, which is 51% below its 10-year median of 19.60. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 74/100 and a GF Value™ of kr7.95 (Fairly Valued). The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Arcoma AB ranks better than 51.31% on this metric.
During the past 12 months, Arcoma AB's average EBITDA Per Share Growth Rate was -34.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Arcoma AB was 62.30% per year. The lowest was -63.80% per year. And the median was 19.60% per year.
Arcoma AB (OSTO:ARCOMA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Arcoma AB 3-Year EBITDA Growth Rate Related Terms
OSTO:ARCOMA vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Arcoma AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Arcoma AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.60% mean?
Arcoma AB (OSTO:ARCOMA) has a 3-Year EBITDA Growth Rate of 9.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Arcoma AB and its competitors. This is 51% below median its historical median of 19.60. According to the industry distribution chart, Arcoma AB ranks #335 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 48.7%.
Is Arcoma AB's 3-Year EBITDA Growth Rate too high?
Arcoma AB's current 3-Year EBITDA Growth Rate of 9.60% is 51% below median its 10-year median of 19.60. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Arcoma AB's value of 9.60% is 18.5% above this industry median. Based on the distribution chart, Arcoma AB ranks #335 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Arcoma AB has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #335 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Arcoma AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Arcoma AB's value of 9.60% is 18.5% above this benchmark. While the company's 10-year median is 19.60 vs. the industry median of 8.10, Arcoma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcoma AB's current 3-Year EBITDA Growth Rate of 9.60% is 18.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current 3-Year EBITDA Growth Rate is 9.60%, which is 51% below median its own 10-year median of 19.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.95, compared to a current price of kr7.96 — trading 0.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.60%, which is 51% below median its 10-year median of 19.60 and 18.5% above the Medical Devices & Instruments industry median of 8.10. Arcoma AB's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current 3-Year EBITDA Growth Rate is 9.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr7.96 is trading 0.1% above its estimated GF Value™ of kr7.95.
GuruFocus considers Arcoma AB to be Fairly Valued.
Key valuation signals for OSTO:ARCOMA:
3-Year EBITDA Growth Rate: 9.60% (51% below median its 10-year median of 19.60)
GF Value™: kr7.95 vs. price of kr7.96 (0.1% above fair value)
Industry Position: 18.5% above the Medical Devices & Instruments median (#335 of 688)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
74GF Score
Get the complete analysis for OSTO:ARCOMA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
